XML 15 R2.htm IDEA: XBRL DOCUMENT v3.7.0.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2017
Dec. 31, 2016
Current assets:    
Cash and cash equivalents $ 43,384 $ 22,895
Accounts receivable, net 1,312 302
Receivable from Sanofi   30,557
Inventory 3,172 2,331
Asset held for sale   16,730
Deferred costs from commercial product sales 500 309
Prepaid expenses and other current assets 2,563 4,364
Total current assets 50,931 77,488
Property and equipment-net 27,920 28,927
Other assets 523 648
Total assets 79,374 107,063
Current liabilities:    
Accounts payable 6,541 3,263
Accrued expenses and other current liabilities 9,076 7,937
Facility financing obligation 57,484 71,339
Deferred revenue-net 2,592 3,419
Deferred payments from collaboration-current 250 1,000
Recognized loss on purchase commitments-current 9,926 5,093
Total current liabilities 85,869 92,051
Note payable to principal stockholder 79,666 49,521
Accrued interest-note payable to principal stockholder   9,281
Senior convertible notes 27,649 27,635
Recognized loss on purchase commitments-long term 99,001 95,942
Deferred payments from collaboration-long term 625  
Warrant liability 605 7,381
Milestone rights liability and other liabilities 7,202 8,845
Total liabilities 300,617 290,656
Commitments and contingencies (Note 11)
Stockholders' deficit:    
Undesignated preferred stock, $0.01 par value-10,000,000 shares authorized; no shares issued or outstanding at June 30, 2017 and December 31, 2016
Common stock, $0.01 par value-140,000,000 shares authorized, 104,615,982 and 95,680,831 shares issued and outstanding at June 30, 2017 and December 31, 2016, respectively 1,046 957
Additional paid-in capital 2,566,960 2,553,039
Accumulated other comprehensive loss (21) (24)
Accumulated deficit (2,789,228) (2,737,565)
Total stockholders' deficit (221,243) (183,593)
Total liabilities and stockholders' deficit $ 79,374 $ 107,063